ArticleFrontiers in immunology2026
Case Report: Sirolimus as management strategy for thrombocytopenia related to ARPC1B deficiency.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biallelic mutations in ARPC1B gene are responsible for an inborn error of immunity (IEI) characterized by thrombocytopenia and combined immunodeficiency with heterogeneous immune-dysregulatory features. Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor, which is successfully used in patients affected by primary or secondary autoimmune cytopenias. We report the case of a patient suffering from refractory/relapsing thrombocytopenia secondary to a previously unreported homozygous variant on ARPC1B and successfully managed with sirolimus. Additional mild immune dysregulatory features, such as lymphoproliferation and autoantibodies, also resolved after sirolimus treatment. Protein's functional analysis showed an interaction between ARPC1B's role in actin cytoskeleton function and mTOR signaling pathway. However, the actin polymerization assay evaluation on samples collected before and after sirolimus treatment showed no significant differences. This result might suggest that the efficacy of sirolimus in controlling thrombocytopenia was mainly due to its immunomodulatory effect to reduce autoimmunity. The absence of a direct effect on actin cytoskeleton may also explain the lack of efficacy of sirolimus in previously reported ARPC1B-deficient patients affected by broader immune dysregulation features, including at least three or more systems involved. Although increased evidence is supporting early hematopoietic stem cell transplantation (HSCT) as an option for more severe broad-spectrum phenotypes, sirolimus could represent a therapeutic option in ARPC1B deficiency in case of a less severe immune-dysregulation phenotype or as a bridge therapy before transplant. Prospective observation can help in defining patients' evolution and prognosis with sirolimus monotherapy, and the risks and benefits of combination strategies with steroids or immune-modulating drugs should be compared with HSCT progress and results in transplant-related mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.